dermatolog reiter buy rais pt
commerci anim health
vaccin product also provid product
servic relat biodevic diagnost
tool genet
requir disclosur end report
view current cl king meet event calendar coverag univers
conduct survey veterinarian differ vet
survey last quarter well vet interview came away optimist
rimadyl maintain role simparica gain share even
price core thesi zoeti grow revenu via strong
companion anim product maintain solid perform
livestock busi drive earn growth effici
initi base stabl strong cash flow dividend share
repurchas view steadi long-term grower attract market
reiter buy rate rais pt
simparica spoke coupl vet simparica drug late
market zoeti use rebat strategi gain penetr contact
believ help compani gain market share although initi
check vet suggest simparica protect time isnt help
believ complianc easiest monthli cycl one vet spoke
think extra day help lack complianc administ
everi day still okay plu extra day protect keep dog
gallipr risk rimadyl competitor petxa
gallipr rate good drug fact name best new
companion anim drug anim pharm said found
vet continu prescrib rimadyl first-lin therapi pain
possibl vet prefer rimadyl see blood
monitor associ nsaid futur revenu sourc
opportun vet said pain cat cancer dog area
need new treatment close nexvet acquisit back
juli think zoeti move safer monoclon antibodi mab
pain cancer pilot pivot studi look forward hear
compani pipelin come earn call
macro mix vet said volum grew
second-lowest rate growth weve seen sinc began survey
said vet higher level optim weve ever seen theyr
expect practic volum growth vs averag
price model updat rais price target base
unchang revis post-tax reform adjust ep estim
previous increas adjust ep
forecast increas ep simpli reflect tax reform
thought stock
although becom littl uneasi valuat stick
buy recommend mani ah compani also lofti
valuat earn basi zoeti cheapest stock group far
addit feel comfort limit downsid risk due share
buyback dividend well benefit foreign exchang fx
figur zoeti reason price ah stock consensu estim
factset inc note growth rate calendar
survey conduct survey differ vet prior quarterli
survey vet randomli select distribut across unit
pain still opportun
ask vet prescrib pain manag surpris
find rimadyl still lead lot rimadyl lead interpret two
way first zoeti done realli good job keep gener nsaid
gallipr take market second perhap
market share gain interestingli spoke pharmaceut profession back
fall told us pet experienc nausea vomit
take aratana gallipr market safer altern nsaid
vomit common side effect note label sure
common realli clinic data shown safer high quantiti
sure side effect would off-set
forty-thre percent vet survey still use rimadyl use gallipr
found interest deramaxx metacam rank higher
gallipr term found one vet said quellin
rest said gener dermaxx rimadyl vca-specif rimadyl
see conflict news one happi rimadyl stay
strong face gener competit competit gallipr
time show rimadyl older-gener drug much market
share lose
page
figur first-lin pain medic dog
interest chang momentum survey ask vet
would switch rimadyl gallipr found whop
said would come year think nausea side effect
price argument made competitor last six month
effect juxtapos current market share data versu expect
gallipr six month ago expect gallipr seriou
effect rimadyl sale mute
page
respondentsoth pleas zoeti rimadyl deal vca gener start gener surgeon mostli use rimadyl deramaxx
vet want chronic kidney diseas ckd select
area new therapi right isnt compound ckd
think pipelin larg pharma includ zoeti aratana
kindr bioscienc kina compound ckd respect
pipelin aratana weight manag ckd cat patient
kindr epocat pivot trial second-most-need drug cat pain
medic aratana look compound pilot/pivot
post-operative pain although didnt dive figur whether
vet demand drug osteoarthr oa pain post-operative pain
assum oa pain
figur vet need new therapi
page
vet want dog new drug indic cancer
pick vet weve discuss cancer drug past veterinarian
consensu opinion seem necessarili new chemotherapi rather
target therapi zoeti bought nexvet last year intent use
mab pain cancer addit weve spoken ceo kindr
bioscienc richard chin discuss sever target human drug
compani studi human medicin includ checkpoint inhibitor
page
figur vet need new therapi dog
figur distribut respons indic need dog
page
note vet particip use slide bar select growth
ask patient volum rather revenu think factor
contribut upward bia data rel idxxa
volum averag vet survey said practic volum
grew compar although fair heavili
weight eight vet said volum decreas
disappoint natur disaster-rel event could
push forward volum prior quarter wellness-typ visit
saw averag volum
figur estim chang quarterli patient volum
page
figur roll five-quart averag estim chang quarterli patient
expect volum interest survey found
far biggest disconnect current volum futur volum
exampl found second-lowest three-month growth rate easier
comp well found highest ever forward estim growth
assum price hold steadi reason assumpt given recent
increas inflat fact price beat inflat recent year
would impli industri grow
would far best growth industri ever seen
figur estim direct patient volum month
page
chang patient quarterli volum
figur estim direct patient volum month
figur roll five-quart averag estim direct patient volum
note specif look veterinarian unusu respons
goal vet interview provid gener view specif
veterinarian psycholog use supplement
interview veterinarian three-vet practic locat texa
use scil chemistri
page
direct volum month
upgrad samsung vet current use scil upgrad scil
samsung analyz summer expir contract ask
henri schein nr own scil analyz scil
samsung analyz cant upgrad sooner said origin bought
analyz financ local bank scil/schein buy
origin agreement weve spoken numer rep three largest
player found lack flexibl scil hardli believ
vet fulli trust accuraci analyz said samsung henri
schein larg high qualiti compani risk put
veterinarian look three major vendor didnt want work
doesnt work distributor said hskaa
nich although dont know mean decis
ultim came samsung analyz abaxi abaxa
 jump samsung analyz price per
month practic get twenti comprehens panel five
panel free equip get would free said
cheaper abaxi offer
entyce- drug veterinarian alreadi bought aratana entyc
accord effect medic inappet
stock prescrib drug no-brain
interview veterinarian four-and-a-half vet practic locat
massachusett use diagnost
satisfi sedivu vet practic happi
sedivu said practic isnt use practic
includ urin sediment analysi well packag origin
thought would run sedivu turn dont trust result
practic fulli integr practic said like
use instrument get better
gallipr rimadyl practic carri gener drug
typic prescrib rimadyl pain practic vet first
choic pharmaceut carri in-hous ask
gallipr said doesnt normal prescrib price said
long-term use pain medic would requir frequent visit even
though gallipr shown better safeti profil said practic
requir regular bloodwork patient prescrib pain medic
includ gallipr even better safeti profil although didnt
directli state answer gave us impress practic look
regular bloodwork prescrib pain med mean continu
see patient regular interv
risk achiev price target
price concess competit
strong growth prospect outsid
page
page
